10-K: Avalo Therapeutics Reports Increased Losses, Eyes Key Trial Data

Avalo Therapeutics reported a significant increase in net loss for 2025, driven by higher R&D and administrative expenses, as it progresses its lead drug candidate, abdakibart, towards a critical Phase 2 data readout in Q2 2026.

Summary

• Net loss for the year ended December 31, 2025, increased to $78.3 million, up from $35.1 million in 2024.
• Research and development expenses rose by $25.6 million to $50.1 million in 2025, primarily due to the Phase 2 LOTUS trial for abdakibart (AVTX-009) in hidradenitis suppurativa (HS).
• General and administrative expenses increased by $5.7 million to $22.9 million in 2025, mainly due to higher stock-based compensation and headcount additions.
• Cash and cash equivalents and short-term investments totaled $98.3 million as of December 31, 2025, with an expected runway into 2028.
• The company completed enrollment in the Phase 2 LOTUS trial for abdakibart in HS in October 2025 and anticipates reporting topline data in the second quarter of 2026.
• The U.S. composition-of-matter patent for abdakibart (AVTX-009) expired in February 2026, with the company planning to primarily rely on biologics regulatory exclusivity.
• The fair value of the derivative liability related to AVTX-007 milestones and royalties increased to $18.0 million as of December 31, 2025, driven by a 41% probability of success and estimated peak annual net sales of $1.7 billion in atopic dermatitis, following a positive Phase 2a clinical trial announcement in September 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the increased net loss and cash burn are concerning, the completion of Phase 2 enrollment for the lead candidate and the upcoming topline data readout present a significant near-term catalyst. The expiration of the composition-of-matter patent for abdakibart is a notable intellectual property challenge, but the company's reliance on regulatory exclusivity and other patent types could mitigate this. The positive development for the out-licensed AVTX-007 also adds some value, though it doesn't directly impact Avalo's cash flow.

Positives

• Cash, cash equivalents, and short-term investments of $98.3 million are expected to fund operations into 2028, providing a reasonable financial runway.
• Completed enrollment in the Phase 2 LOTUS trial for abdakibart (AVTX-009) in hidradenitis suppurativa (HS) in October 2025, indicating progress in its lead program.
• Anticipated topline data readout for the Phase 2 LOTUS trial in Q2 2026 could be a significant value inflection point.
• AVTX-007, an out-licensed asset, showed positive Phase 2a clinical trial results in atopic dermatitis in September 2025, increasing the fair value of associated milestone and royalty payments.

Negatives

• Net loss significantly increased to $78.3 million in 2025 from $35.1 million in 2024.
• Cash used in operating activities was $51.5 million in 2025, indicating a substantial cash burn rate.
• The U.S. composition-of-matter patent for the lead product candidate, abdakibart (AVTX-009), expired in February 2026, increasing reliance on regulatory exclusivity and other patent types.
• The company is substantially dependent on the success of a single lead product candidate, abdakibart (AVTX-009), increasing business risk.
• Legacy programs (Quisovalimab (AVTX-002), AVTX-006, AVTX-008, AVTX-913) are not currently being pursued clinically, and strategic alternatives are being explored, indicating a narrowed pipeline focus.

Risks

• Clinical trials of product candidates may fail to demonstrate safety and efficacy, leading to additional costs, delays, or inability to complete development and commercialization.
• Delays in clinical testing could delay regulatory approvals, increase costs, and harm the business.
• Inability to obtain marketing approval for product candidates, or approval for narrower indications or with costly post-approval obligations.
• Reliance on third parties to conduct and monitor clinical trials, with potential for failure to meet deadlines or contractual duties.
• Product candidates are in early to mid-stages of development, with significant risk of failure or delays.
• Limited resources may be expended on a particular product candidate or indication that proves less profitable or successful.
• The marketing approval processes are lengthy, time-consuming, costly, and inherently unpredictable.
• Reliance on third parties for manufacturing product candidates increases the risk of insufficient quantities or unacceptable costs.
• Expectation to require additional capital in the future, which might not be available on acceptable terms, or at all, potentially forcing delays or termination of development efforts.
• Even with marketing approval, product candidates may not achieve broad market acceptance, limiting revenue and preventing profitability.
• Inability to obtain or maintain intellectual property rights, or insufficient patent protection, could allow competitors to commercialize similar products.
• Breach of license and development agreements could lead to loss of ability to develop and commercialize product candidates.
• Failure to attract and retain management and other key personnel, as well as board members, could hinder business plan implementation.
• Price volatility of common stock, potentially unrelated to operating performance, making it difficult for investors to assess value.
• Significant net losses incurred since inception, with expectations of continued losses.
• Adverse effects from unforeseen global events, natural disasters, or pandemics on business continuity and disaster recovery plans.
• Potential for employees, principal investigators, CROs, and consultants to engage in misconduct or improper activities, including non-compliance with regulatory standards and insider trading laws.
• Uncertainty regarding the extent to which FDA's regulations, policies, and decisions may become subject to increasing legal challenges, delays, or changes due to recent Supreme Court decisions.
• Risks associated with short-term liquid investments, including potential losses in fair value or liquidity issues.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes due to ownership changes or insufficient taxable income.
• Fluctuations in quarterly and annual operating results, making future results difficult to predict.
• No approved commercial products, meaning no expected revenues from product sales for the foreseeable future.
• Changes in product candidate manufacturing or formulation may result in additional costs or delays.
• Intense competition and rapid technological change in the biotechnology and pharmaceutical industries.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Difficulties in managing growth and expanding operations successfully.
• Potential conflicts of interest for the Chief Executive Officer due to a royalty agreement on a legacy program (AVTX-006).
• Claims by third parties asserting misappropriation of intellectual property or ownership of company intellectual property.
• Changes in patent law could diminish the value of patents.
• Inability to protect intellectual property rights throughout the world.
• Increased costs and obligations as a public company, including compliance with corporate governance and financial reporting practices.
• Provisions in charter documents and Delaware law may have antitakeover effects.
• Rights associated with Series D and Series E preferred stock may concentrate control of the Board of Directors.
• Risks arising from the use of new and evolving technologies, such as artificial intelligence, including cybersecurity, data privacy, and intellectual property risks.

Future Outlook

The company's current focus is on completing the Phase 2 LOTUS trial for abdakibart (AVTX-009) in HS, preparing for the anticipated topline data readout in the second quarter of 2026, and planning for Phase 3 trial(s). Operating expenses are expected to be largely consistent with 2025 through the Phase 2 data readout, with expenses beyond that point highly dependent on trial outcomes. The company expects to require additional capital in the future, particularly prior to any Phase 3 development and/or indication expansion.

Management Comments

• Management's primary evaluation of our success is the ability to progress its programs towards commercialization or opportunistically out-licensing rights to indications or geographies.
• We believe the ability to achieve the next anticipated milestone represents our most immediate evaluation point as to the progression of our pipeline.

Industry Context

StockSavvy.ai notes that Avalo Therapeutics operates in the highly competitive biopharmaceutical industry, specifically targeting immune-mediated inflammatory diseases with a focus on IL-1 inhibition. The hidradenitis suppurativa (HS) market is characterized by substantial unmet needs, with current approved biologics (e.g., adalimumab, secukinumab, bimekizumab) achieving HiSCR50 in only ~50% of patients. The global HS market is projected to grow to over $10 billion by 2035, indicating significant commercial potential for effective new treatments. Avalo faces competition from major pharmaceutical and biotechnology companies with greater resources and experience, including those developing TNF-alpha and IL-17 inhibitors for HS, as well as other novel IL-1 targeting agents.

Comparison to Industry Standards

• Currently approved biologics for HS, such as adalimumab (anti-TNF-), secukinumab (anti-IL-17A), and bimekizumab (dual anti-IL-17A/F), achieve a Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) in approximately 50% of patients. More stringent thresholds like HiSCR75/90 are achieved in even fewer individuals.
• Avalo's abdakibart (AVTX-009) is being evaluated against these benchmarks, with primary efficacy endpoint being HiSCR75 at Week 16, and secondary objectives including HiSCR50 and HiSCR90, as well as IHS4, draining fistula count, AN count, and PGA Skin Pain reduction.

Management Changes

Corporate Governance

Related Party Transactions

• Royalty Agreement with entities affiliated with Dr. Garry Neil (Chief Executive Officer and Chairman of the Board) and Mike Cola (former CEO) for AVTX-006, entitling them to a low-single digit percentage of aggregate net sales.
• Sale of economic rights to future milestone and royalty payments for AVTX-501, AVTX-007, and AVTX-611 to ES Therapeutics, LLC, an affiliate of Armistice Capital LLC, which was a significant stockholder and had board representation at the time of the transaction.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity raises and conversion of preferred stock. The stock price is subject to high volatility, especially around clinical trial data readouts. Increased net losses and cash burn could negatively impact investment value.
• **Employees:** Benefit from competitive salaries, bonuses, and equity ownership plans (stock options, RSUs, PSUs). New inducement award plans aim to attract and retain talent. However, reliance on a single lead product candidate could create employment exposure risk.
• **Customers (future):** Potential for new treatment options for immune-mediated inflammatory diseases, particularly hidradenitis suppurativa, if abdakibart is successfully developed and commercialized.
• **Suppliers/CDMOs:** Continued reliance on third-party contract development and manufacturing organizations (CDMOs) for product candidate supply, indicating ongoing business for these partners.
• **Creditors:** The company's need for additional capital and history of operating losses may influence terms for future debt financing.

Next Steps

• Report topline data from the Phase 2 LOTUS trial for abdakibart (AVTX-009) in hidradenitis suppurativa in the second quarter of 2026.
• Plan for Phase 3 trial(s) for abdakibart (AVTX-009) following the Phase 2 data readout.
• Explore further indication expansion for abdakibart (AVTX-009).
• Acquire or in-license rights to and/or develop targeted, complementary differentiated preclinical and clinical stage compounds that treat immune-mediated inflammatory disease.
• Opportunistically out-license rights to compounds, indications, or geographies for legacy programs (Quisovalimab (AVTX-002), AVTX-006, AVTX-008, AVTX-913).
• Seek additional capital through equity offerings, debt financings, collaborations, licensing arrangements, or other similar arrangements, particularly before Phase 3 development.

Key Dates

Recommendation

Avalo Therapeutics presents a high-risk, high-reward profile. The significant increase in net loss and cash burn, coupled with the expiration of the composition-of-matter patent for its lead candidate, abdakibart, are notable concerns. However, the company has a cash runway into 2028 and a critical Phase 2 data readout for abdakibart in Q2 2026, which could be a major value inflection point. The positive Phase 2a results for the out-licensed AVTX-007 also provide some validation of its pipeline assets, albeit indirectly. Given the substantial uncertainty surrounding clinical trial outcomes and future financing needs, but also the potential for significant upside from positive data, a 'hold' recommendation is appropriate for investors with a high-risk tolerance who are willing to await the upcoming clinical catalysts.

Keywords

Biotechnology, Clinical Stage, IL-1, Hidradenitis Suppurativa, HS, Abdakibart, AVTX-009, Monoclonal Antibody, Inflammatory Diseases, Drug Development, Clinical Trials, SEC Filing, 10-K, Financial Results, Cash Runway, Intellectual Property, Regulatory Exclusivity, Orphan Drug, Biologics, Pharmaceutical, Corporate Governance, Risk Management